Summary
CJC-1295 and Ipamorelin are two distinct research peptides that target the somatotropic axis through complementary mechanisms. CJC-1295 is a modified GHRH analog; Ipamorelin is a selective growth-hormone-releasing peptide (GHRP) with high specificity at the ghrelin receptor (GHS-R1a).
Overview
The combination pairs a GHRH-receptor agonist (CJC-1295) with a ghrelin-receptor agonist (Ipamorelin). The two receptors converge on growth-hormone-releasing cell populations in the anterior pituitary, which is the basis for studying the combination as a multi-receptor reference preparation.
Research Background
CJC-1295 was described by Teichman et al. (2006) as a synthetic GHRH analog with modifications that extend its functional half-life. Ipamorelin was described by Raun et al. (1998) as a selective GHRP with high affinity at the ghrelin receptor and minimal off-target activity at cortisol or prolactin pathways.
Mechanisms Studied
Mechanistic studies focus on complementary receptor engagement — GHRH-receptor signaling on one side and ghrelin-receptor signaling on the other. Each receptor activates GHRH-axis cell populations through a distinct second-messenger pathway, which is the basis for combination preparations being studied as multi-pathway reference compounds.
Published Research Summary
Teichman et al. (2006) describe the pharmacology of CJC-1295. Raun et al. (1998) describe the receptor selectivity profile of Ipamorelin. Combined-preparation literature is more limited but generally references both component papers and frames the combination as a complementary multi-receptor engagement of the somatotropic axis.
Quality & Verification
For research compounds, lot-level documentation is the starting point for any analytical work. Researchers commonly examine batch-specific Certificates of Analysis, reversed-phase HPLC purity readouts, mass-spectrometry confirmation of molecular weight, and lot identification to evaluate compound identity, purity, and consistency before downstream experiments.